-The Hindu Business Line India is being too accommodating of MNCs The Centre is needlessly apologetic about our IPR laws. It set up an IPR ‘think tank’ in October 2014, perhaps responding to a view that our IPRs are not strong enough to invite foreign investment. Last January, Prime Minister Modi and President Obama issued a joint statement which “committed to establish an annual high-level Intellectual Property Working Group”. In November, Modi...

-The Times of India NEW DELHI: For bringing down prices of medicines for critical diseases like cancer, HIV and diabetes, the government has revised the national list of essential medicines (NLEM) to add 106 more drugs while 70 other drugs, which are not prescribed frequently or where better alternatives are now available in the market, have been taken off the list. This means, the total number of essential medicines, prices of which...

-DNA Despite a certain amount of progress in the past decade or so, the report points out glaring gaps in healthcare infrastructure in the country -- "low resource allocation, low emphasis on primary health care, poor utilisation of human resources," as Professor K Srinath Reddy, one of the co-authors said. Yet another report on India's troubled health care system pointed out the country's poor performance across health indicators, despite economic advantages....

-The Times of India MUMBAI: When World AIDS Day is observed across the globe on December 1, India will enter the third, and perhaps the most perplexing decade of its HIVAIDS epidemic. The first 29 years were marked with victory as the human immunodeficiency virus (HIV) metamorphosed from being the deadliest word in public health to just another chronic disease such as diabetes or hypertension. that can be managed well with medicines....

-The Times of India NEW DELHI: In a move that comes as a huge relief to patients of chronic Hepatitis C, the apex committee of the Central Drugs Standard Control Organisation (CDSCO) has granted a waiver of local trials for crucial new direct-acting antiviral drugs treating the disease. The waiver for sofosbuvir and ledipasvir co-formulation and for daclatasvir is expected to bring the generic version of these drugs, which cost a fraction...